With the introduction of the new GMS contract, GPs need to treat patients efficiently and effectively in order to achieve Quality and Outcomes Framework points. The VALUE trial has shown that aggressive treatment of hypertension minimises the risk of further cardiovascular outcomes. Dr Sarah Jarvis, a GP, notes that applying the results of this trial to clinical practice will help GPs reach their targets and protect hypertensive patients against further health risks such as new onset diabetes.
Investing in General Practice: The New General Medical Services Contract . BMA, February 2003.
2.
Department of Health.National Service framework for Diabetes. London2003.
3.
National Institute of Clinical Excellence : Inherited clinical guideline -Management of type 2 diabetes: management of blood pressure and blood lipids. National Institute of Clinical Excellence, October 2002.
4.
Department of Health.National Service framework for Coronary Heart Disease. London2001.
5.
Dickstein K.ELITE II and Val-HEFT are different trials: together what do they tell us?Curr Controls Trials Cardiovasc Med2001; 2:240-3.
6.
Pfeffer MA, Swedberg K., Granger CB et al. CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet2003;362:759-66.
7.
Parving HH, Lehnert H., Brocher-Mortensen J. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med2001; 345:910-12.
8.
Law MR, Wald NJ, Morris JK, Jordan REValue of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ2003 ;326: 1427-31.
9.
Julius S., Kjeldsen S., Weber M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet2004;19:2022-31.
10.
Williams B. , Poulter N., Brown MJ et al. Guidelines for the management of hypertension: report of the fourth working party of the British Hypertension Society - BHS IV. J Hum Hypert2004;18:139-85.
11.
Weber MA, Julius S., Kjeldsen SE et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet2004;363:2049-51.
12.
Dahlof B., Devereux R., Kjeldsen S. et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet2002; 359:995-1010.
13.
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA2002; 288:2981-97.
